Brief: Bioporto Achieves Targeted Enrollment In Clinical Study Supporting FDA De Novo Submission For Ngal Test In U.S.
28/06/2022 20:00
June 28 (Reuters) - Bioporto A/S BIOPOR.CO :
* BIOPORTO ACHIEVES TARGETED ENROLLMENT IN CLINICAL STUDY
SUPPORTING FDA DE NOVO SUBMISSION FOR NGAL TEST IN U.S.
* BIOPORTO ANTICIPATES SUBMISSION OF ITS DE NOVO APPLICATION
TO
FDA BY Q4 OF 2022
Source text for Eikon: ID:nGNE8BsbJF
Further company coverage: BIOPOR.CO
((Reuters.Briefs@thomsonreuters.com;))